Literature DB >> 33147656

Differences in Prescription Stimulant Misuse Motives Across Adolescents and Young Adults in the United States.

Ty S Schepis1,2, Jason A Ford3, Timothy E Wilens4,5, Christian J Teter6, Sean Esteban McCabe7,8,9,10,11.   

Abstract

OBJECTIVE: While prescription stimulant misuse (PSM) is common in adolescents and young adults (AYAs), PSM motives are poorly understood. This study examined a number of PSM motives across the AYA age spectrum using the 2015-2018 National Survey on Drug Use and Health.
METHODS: In all, 86,918 AYAs (aged 14-25 years) were included. Individual PSM motives (eg, to study) and motive categories (ie, cognitive enhancement only, recreational only, weight loss only, and combined motives) were examined by age. Logistic regression models examined links between individual motives or motive categories and educational status, substance use, DSM-IV substance use disorders (SUD), and mental health correlates.
RESULTS: Significant differences were found across AYAs in cognitive enhancement only (14 years = 40.4%; 24 and 25 years = 71.2%; P < .0001) and recreational only (14 years = 25.8%; 24 and 25 years = 9.8%; P < .0001) or combined PSM motives, (14 years = 32.3%; 24 and 25 years = 18.0%; P = .008); college students and graduates had particularly high rates of cognitive enhancement only (college = 78.2%; graduates = 74.7%; non-college = 63.5%). Recreational-only and combined motives were significantly elevated in AYAs with any past-year SUD, especially to get high (78%-136% higher in those with SUD; P ≤ .001). While any PSM was associated with higher odds of SUD and mental health outcomes, including suicidal ideation, odds were highest for recreational or combined motives.
CONCLUSIONS: Cognitive enhancement with PSM occurs more often in young adults compared to adolescents, college students endorse more cognitive enhancement than those not in school, and the presence of any PSM in AYAs is linked to more substance use, suicidal ideation, and other psychopathology. PSM prevention in adolescents as well as screening and intervention among AYA is highly recommended. © Copyright 2020 Physicians Postgraduate Press, Inc.

Entities:  

Year:  2020        PMID: 33147656     DOI: 10.4088/JCP.20m13302

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

1.  Characterizing prescription stimulant nonmedical use (NMU) among adults recruited from Reddit.

Authors:  Suzanne K Vosburg; Rebekkah S Robbins; Kevin M Antshel; Stephen V Faraone; Jody L Green
Journal:  Addict Behav Rep       Date:  2021-09-11

2.  Prescription drug and alcohol simultaneous co-ingestion in U.S. young adults: Prevalence and correlates.

Authors:  Ty S Schepis; Sean Esteban McCabe; Jason A Ford
Journal:  Exp Clin Psychopharmacol       Date:  2021-08-19       Impact factor: 3.157

3.  Behavioral Willingness, Descriptive Normative Perceptions, and Prescription Stimulant Misuse among Young Adults 18-20.

Authors:  Nicole Fossos-Wong; Dana M Litt; Kevin M King; Jason R Kilmer; Anne M Fairlie; Mary E Larimer; Christine M Lee; Irene M Geisner; M Dolores Cimini; Melissa A Lewis
Journal:  Subst Use Misuse       Date:  2021-11-23       Impact factor: 2.362

4.  Within-Person Predictors of Same-Day Alcohol and Nonmedical Prescription Drug Use Among Youth Presenting to an Urban Emergency Department.

Authors:  Jason E Goldstick; Erin E Bonar; Matthew Myers; Amy S B Bohnert; Maureen A Walton; Rebecca M Cunningham
Journal:  J Stud Alcohol Drugs       Date:  2022-01       Impact factor: 2.582

5.  Potential risk groups and psychological, psychosocial, and health behavioral predictors of pharmacological neuroenhancement among university students in Germany.

Authors:  Sebastian Heller; Ana Nanette Tibubos; Thilo A Hoff; Antonia M Werner; Jennifer L Reichel; Lina M Mülder; Markus Schäfer; Daniel Pfirrmann; Birgit Stark; Thomas Rigotti; Perikles Simon; Manfred E Beutel; Stephan Letzel; Pavel Dietz
Journal:  Sci Rep       Date:  2022-01-18       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.